Halofantrine Safety, Tolerance and Metabolism Studies.
Abstract
Halofantrine HCl is an antimalarial drug approved by the FDA for the treatment of mild to moderate malaria caused by Plasm odium falciparum or Plasm odium vivax(1). The present study was designed to investigate the safety, tolerance and pharmacokinetics of halofantrine HCl given in multiple doses in a Phase I study as part of the overall development of halofantrine as a prophylactic antimalarial drug.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 1997
- Accession Number
- ADA364323
Entities
People
- Ajaz Hussain
- Darrell R. Abernethy
- David Flockhart
- David L. Wesche
- Jean Barbey
Organizations
- Food and Drug Administration